In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients

Chemotherapy

Volumn 50, Issue 5, 2004, Pages 214-220

  Rolston, Kenneth V I ^a   Vaziri, Irfan ^a   Frisbee Hume, Susan ^a   Streeter, Harriet ^a   LeBlanc, Barbara ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Gatifloxacin; In vitro activity; Neutropenic cancer

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; TROVAFLOXACIN;

ACHROMOBACTER XYLOSOXIDANS; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS; CONTROLLED STUDY; DRUG ACTIVITY; ENTEROCOCCUS FAECALIS; GENETIC SUSCEPTIBILITY; LISTERIA MONOCYTOGENES; MICROCOCCUS; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RHODOCOCCUS EQUI; ROTHIA;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS; FERMENTATION; FLUOROQUINOLONES; FOLLOW-UP STUDIES; GRAM-NEGATIVE AEROBIC BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; NEOPLASMS; NEUTROPENIA; QUINOLONES; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 9144246505     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081708     Document Type: Article

References (51)

1. Bodey GP: Infection in cancer patients: A continuing association. Amer J Med 1986; 81(suppl lA):11-26.
2. Koll BS, Brown AE: The changing epidemiology of infections at cancer hospitals. Clin Inf Dis 1993; 17(suppl 2):S322-S328.
3. Zinner SH: Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria. Clin Inf Dis 1999; 29: 490-494.
4. The GIMEMA Infection Program: Prevention of bacterial infection in neutropenic patients with hematologic malignancies: A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 1991; 115:7-12.
5. Engels EA, Lau J, Barza M: Efficacy of quinolone prophylaxis in neutropenia cancer patients: A meta-analysis. J Clin Oncol 1998; 16:1179-1187.
6. Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E: Prophylaxis with fluoroquinolones in neutropenic patients: A meta-analysis. Clin Infect Dis 1996; 23: 795-805.
7. Meunier F, Zinner SH, Gaya H, Calandra T, Viscoli C, Klastersky J, et al: Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumor. European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother 1991; 35: 873-878.
8. Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante E, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K, Holmes F, Elting L, Bodey GP: Outpatient treatment of febrile episodes in low risk neutropenic cancer patients. Cancer 1993; 71: 3640-3646.
9. Malik IA, Kahan WA, Karim M, Aziz Z, Khan MA: Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial. Am J Med 1995; 98; 224-231.
10. Mullen CA, Petropoulos D, Roberts WM, Rytting M, Ziph T, Chan KW, Culbert SJ, Danielson M, Jeha S, Kuttesch JF, Rolston K: Outpatient treatment of febrile neutropenia in low risk pediatric cancer patients. Cancer 1999; 86:126-134.
11. Dholakia, N, Rolston KVI, Ho DH, LeBlanc B, Bodey GP: Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother 1994; 38: 848-852.
12. Rolston KVI, Ho DH, LeBlanc B, Streeter H, Dvorak T: In vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. J Antimicrob Chemother 1997;39(suppl B):15-22.
13. Jones RN: Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29:495-502.
14. Rolston KVI: Use of the quinolones in immunocompromised patients; in Andriole VT (ed): The Quinolones, ed 3. San Diego, Academic Press, 2000, pp 343-369.
15. Fung-Tomc J, Minassian B, Kolek B, Washo T, Huczko E, Bonner D: In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000; 45: 437-446.
16. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - ed 5. MIC Testing Supplemental Tables M7-A5. Wayne, NCCLS, 2000.
17. Rolston KVI, Frisbee-Hume S, LeBlanc BM, Streeter H, Ho DH: Antimicrobial activity of novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients. Diagn Microbiol Infect Dis 2002; 44: 187-194.
18. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R: Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38:681-687.
19. Rolston KVI: Commentary: Chemoprophylaxis and bacterial resistance in neutropenic patients. Infect Dis Clin Pract 1998; 7: 202-204.
20. Ito T, Kojima K, Koizumi K, Nagano H, Nishino T: Inhibitory activity of DNA gyrase and intracellular accumulation of quinolones: Structure-activity relationship of Q-35 analogs. Biol Pharm Bull 1994; 17: 927-930.
21. Zhao X, Xu C, Domagala J, Drlica K: DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA 1997; 94: 13991-13996.
22. Zhao X, Wang JY, Xu C, Dong Y, Zhou J, Domagala J, Drlica K: Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother 1998; 42: 956-958.
23. Rosen JE, Chen D, Prahalad AK, Spratt TE, Schulter G, Willliams GM: A fluoroquinolone antibiotic with a methoxy group at the 8 position yields reduced generation of 8-oxo-7, 8-dihydro-2′-deoxyguanosine after ultraviolet-A irradiation. Toxicol Appl Pharmacol 1997;145: 381-387.
24. Boswell EJ, Andrews JM, Jevons G, Wise R: Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother 2002; 50: 495-502.
25. Zhanel GG, Ennis K, Vercaigne L, Walkty A, Gin AS, Embil J, Smith H, Hoban DJ: A critical review of the fluoroquinolones: Focus on respiratory infections. Drugs 2002; 62: 13-59.
26. Jones RN, Pfaller MA: In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY antimicrobial surveillance program. Clin Infect Dis 2000; 31(suppl 2):S16-S23.
27. Naber KG, Hollauer K, Kirchbauer D, Witte M: In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections. Int J Antimicrob Agents 2000; 16: 239-243.
28. Gordon KA, Pfaller MA, Jones RN, the SENTRY Participants Group: BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY antimicrobial surveillance programme (2000). J Antimicrob Chemother 2002; 49; 851-855.
29. Sader HS, Pfaller MA, Jones RN, Doern GV, Gales AC, Winokur PL, Kugler KC: Bacterial pathogens isolated from patients with bloodstream infections in Latin America, 1997: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. Braz J Infect Dis 1999; 3: 97-110.
30. Gales AC, Sader HS, Mendes RE, Jones RN: Salmonella spp. isolates causing bloodstream infections in Latin America: Report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 44: 313-318.
31. Wenzler S, Schmidt-Eisenlohr E, Daschner F: Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections. Chemotherapy 2004; 50: 40-42.
32. Wang M, Sahm DF, Jacoby GA, Zhang Y, Hooper DC: Activities of newer quinolones against Escherichia coli and Klebsiella pneumoniae containing the plasmid-mediated quinolone resistance determinant qnr. Antimicrob Agents Chemother 2004; 48: 1400-1401.
33. Garrison MW, Schimmels JA, Madaras-Kelly KF: In vitro pharmacodynamic activity of gatifloxacin, gemifloxacin, moxifloxacin and levofloxacin against Streptococcus pneumoniae containing specific mutations in DNA gyrase and topoisomerase. IV. Diagn Microbiol Infect Dis 2003; 47: 587-593.
34. Pendland SL, Losnedahl KJ, Schriever CA: In vitro activity of gatifloxacin, a novel fluoroquinolone, compared with that of ciprofloxacin against Legionella spp. J Antimicrob Chemo ther 1999; 44: 295-297.
35. Dubois J, St-Pierre C: In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. Diagn Microbiol Infect Dis 1999; 33: 261-265.
36. Heinemann B, Wisplinghoff H, Edmond H, Seifert H: Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumanii strains. Antimicrob Agents Chemother 2000; 44: 2211-2213.
37. Weiss K, Restieri C, De Carolis E, Laverdière M, Guay M: Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia . J Antimicrob Chemother 2000; 45: 363-365.
38. Rodriguez JC, Ruiz M, Lopez M, Royo G: In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002; 20: 464-467.
39. Tomioka H, Sata K, Akaki T, Kajitani H, Kawahara S, Sakatani M: Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155) and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43: 3001-3004.
40. Rhomberg PR, Jones RN: In vitro activity of 11 antimicrobial agents, including gatifloxacin and GAR936, tested against clinical isolates of Mycobacterium marinum. Diagn Microbiol Infect Dis 2002; 42: 145-147.
41. Kraiczy P, Weigand J, Wichelhaus TA, Heisig P, Backes H, Schafer V, Acker G, Brade V, Hunfeld KP: In vitro activities of fluoroquinolones against the spirochete Borrelia burgdorferi. Antimicrob Agents Chemother 2001;45: 2486-2494.
42. Biedenbach DJ, Croco MAT, Barrett TJ, Jones RN: Comparative in vitro activity of gatifloxacin against S. maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods. Eur J Clin Microbiol Infect Dis 1999; 18: 428-431.
43. Jones RN, Barrett MS, Pfaller MA: In vitro activity of gatifloxacin tested against anaerobic bacteria by reference agar dilution and E test methods. Clin Microbiol Infect 1999; 5: 577-579.
44. Appelbaum PC: Quinolone activity against anaerobes. Drugs 1999; 58(suppl 2):60-64.
45. Rolston KVI, Bodey GP: Infections in patients with cancer; in Holland JF, Frei E (eds): Cancer Medicine. Hamilton, Decker, 2000, pp 2407-2432.
46. Rolston KVI, Tarrand JJ: Pseudomonas aeruginosa - Still a frequent pathogen in patients with cancer: 11-year experience from a comprehensive cancer center. Clin Infect Dis 1999;29: 463-464.
47. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS: 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-751.
48. Diekema DJ, Jones RN, Rolston KV: Antimicrobial activity of gatifloxacin compared to seven other compounds tested against grampositive organisms isolated at 10 cancer-treatment centers. Diagn Microbiol Infect Dis 1999; 34: 37-43.
49. Fish DN, Choi MK, Jung R: Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002; 50: 1045-1049.
50. Critchley IA, Sahm DF, Kelly LJ, Karlowsky JA: In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli. Chemotherapy 2003; 49: 44-48.
51. Sader HS, Huynh HK, Jones RN: Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and β-lactams tested against gram-negative bacilli. Diagn Microbiol Infect Dis 2003; 47: 547-550.